A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease ; volume:20 ; number:1 ; day:19 ; month:8 ; year:2022 ; pages:1-17 ; date:12.2022
Journal of translational medicine ; 20, Heft 1 (19.8.2022), 1-17, 12.2022
- Creator
-
Ferro, Yvelise
Pujia, Roberta
Mazza, Elisa
Lascala, Lidia
Lodari, Oscar
Maurotti, Samantha
Pujia, Arturo
Montalcini, Tiziana
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-022-03579-1
- URN
-
urn:nbn:de:101:1-2022110821221178811110
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ferro, Yvelise
- Pujia, Roberta
- Mazza, Elisa
- Lascala, Lidia
- Lodari, Oscar
- Maurotti, Samantha
- Pujia, Arturo
- Montalcini, Tiziana
- SpringerLink (Online service)
Other Objects (12)
Non-alcoholic fatty liver disease
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
Correction to: In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
Non-alcoholic fatty liver disease
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
Correction to: In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
Non-alcoholic fatty liver disease
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease